Lv1
68 积分 2024-02-20 加入
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
9天前
已完结
Heteroaryl Glutarimides and Dihydrouracils as Cereblon Ligand Scaffolds for Molecular Glue Degrader Discovery
1个月前
已完结
Apotex wins latest round in generic Paxil litigation
7个月前
已完结
Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity
9个月前
已完结
Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists
9个月前
已完结
Drugging the undruggable RAS: Mission Possible?
10个月前
已完结
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers
10个月前
已完结
Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers—Reply
10个月前
已完结
Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers
10个月前
已完结
皖公网安备34019202002308
